Clinical Trials
21 trialsNCT07601607 2026-05-22
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07597941 2026-05-20
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
The Affiliated People's Hospital of Ningbo University
Phase 2/3 Not yet recruiting
NCT07428486 2026-05-07
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03913949 2026-05-01
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting
NCT04501120 2026-04-29
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT05147467 2026-03-27
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT07398638 2026-02-10
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07272499 2025-12-09
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
Phase 2 Recruiting
NCT07255963 2025-12-01
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06389292 2025-11-25
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT04496349 2025-11-04
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT07159906 2025-09-08
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1/2 Not yet recruiting
NCT04260217 2025-08-19
MAPLE-1
Ascentage Pharma Group Inc.
Phase 1 Completed
NCT04494503 2025-04-16
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT05701306 2025-02-25
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT03537482 2024-08-19
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
Phase EARLY_PHASE1 Recruiting
NCT04946864 2024-08-19
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Suspended
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04964518 2023-10-25
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04674514 2023-03-07
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT05495035 2023-03-02
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown